46
Participants
Start Date
September 1, 2021
Primary Completion Date
January 5, 2022
Study Completion Date
May 11, 2022
INO-4201
One dose of 1 mg of INO-4201 in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
Placebo
One dose of normal saline in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
Geneva University Hospitals, Geneva
Collaborators (1)
Defense Advanced Research Projects Agency
FED
Global Urgent and Advanced Research and Development (GuardRX)
UNKNOWN
Inovio Pharmaceuticals
INDUSTRY
University of Geneva, Switzerland
OTHER